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Abstract
Introduction: The aim of this study was to investigate both the effects of chronic treatment with atrial natriuretic peptide
(ANP) on systolic blood pressure (SBP), cardiac nitric oxide (NO) system, oxidative stress, hypertrophy, fibrosis and apoptosis
in spontaneously hypertensive rats (SHR), and sex-related differences in the response to the treatment.
Methods: 10 week-old male and female SHR were infused with ANP (100 ng/hr/rat) or saline (NaCl 0.9%) for 14 days
(subcutaneous osmotic pumps). SBP was recorded and nitrites and nitrates excretion (NOx) were determined. After
treatment, NO synthase (NOS) activity, eNOS expression, thiobarbituric acid-reactive substances (TBARS) and glutathione
concentration were determined in left ventricle, as well as the activity of glutathione peroxidase (GPx), catalase (CAT) and
superoxide dismutase (SOD). Morphological studies in left ventricle were performed in slices stained with hematoxylin-eosin
or Sirius red to identify collagen as a fibrosis indicator; immunohistochemistry was employed for identification of
transforming growth factor beta; and apoptosis was evaluated by Tunel assay.
Results: Female SHR showed lower SBP, higher NO-system activity and less oxidative stress, fibrosis and hypertrophy in left
ventricle, as well as higher cardiac NOS activity, eNOS protein content and NOx excretion than male SHR. Although ANP
treatment lowered blood pressure and increased NOS activity and eNOS expression in both sexes, cardiac NOS response to
ANP was more marked in females. In left ventricle, ANP reduced TBARS and increased glutathione concentration and activity
of CAT and SOD enzymes in both sexes, as well as GPx activity in males. ANP decreased fibrosis and apoptosis in hearts from
male and female SHR but females showed less end-organ damage in heart. Chronic ANP treatment would ameliorate
hypertension and end-organ damage in heart by reducing oxidative stress, increasing NO-system activity, and diminishing
fibrosis and hypertrophy.
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Introduction
It is now universally accepted that blood pressure and the risk of
cardiovascular disease is much higher in men than in age-matched
premenopausal women, but this difference diminishes after
menopause suggesting a protective role of estrogens in the
regulation of blood pressure and in cardiovascular and renal
protection.
The spontaneously hypertensive rat (SHR) is a model of
androgen and angiotensin II-dependent hypertension [1]. SHR
present endothelial dysfunction, an increase in oxidative stress and
vasoconstrictor factors, a decrease in the bioavailability and
effectiveness of nitric oxide (NO), and elevated plasma levels of
atrial natriuretic peptide (ANP) [2,3]. As in humans, SHR exhibit
sex differences in blood pressure, with males having higher blood
pressure than females [4].
On the other hand, essential hypertension often leads to
hypertrophic cardiomyopathy [5]. In this regard, SHR develops
left ventricular hypertrophy, showing an increased cardiac fibrosis,
in response to elevated ventricular volume or pressure overload
[6].
It is well known that estrogens affect cardiovascular function,
either by decreasing blood pressure directly or by modifying
production of endothelium-derived factors [7–9]. In ovariecto-
mized rats, estradiol treatment reduces blood pressure and
increases the synthesis and release of ANP [10]. Indeed, in human
studies, higher circulating levels of ANP have been observed in
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cgi/content/full/26/7/1524-R13-099283#R13-099283 We have
previously provided evidence that acute ANP injection induces a
hypotensive effect by enhancement of cardiovascular NO-synthase
(NOS) activity in both normotensive and hypertensive rats [13–
15]. In addition, it has been shown that the anti-inflammatory,
anti-apoptotic and anti-fibrotic effects of estrogens on the
cardiovascular system could be mediated, at least in part, by
NO production [16].
Oxidative stress is an imbalance between the production of free
radicals and antioxidant defense mechanisms. Increased produc-
tion of reactive oxygen species (ROS) has been associated with
development of hypertension [17]. ANP exerts protective effects
against oxidative stress and in human studies it has been shown
that ANP infusion has antioxidant effects, reducing superoxide
anion production in myocytes [18]. On the other hand, the
inhibition of phospholipase D activity, as well as the decrease of
pH and intracellular calcium by ANP, is a way of protecting the
vascular wall against oxidative stress [19]. In addition, ANP
activates cardiomyocytes particulate guanylyl cyclase-coupled
natriuretic peptide receptor A (NPR-A) and increases intracellular
cGMP levels. The subsequent cGMP stimulation of protein kinase
G suppresses the induction of NADPH oxidase, and hence
decreases the amount of superoxide generated by this enzyme
[20]. Experimental studies show that genetic deletion of estrogen
receptor b results in hypertension in male and female mice [21]
and in hypertensive rats, and estrogen deficiency results in
endothelial dysfunction and oxidative stress [22].
We therefore hypothesized that chronic ANP treatment in SHR
would ameliorate hypertension and end-organ damage in heart by
reducing oxidative stress, increasing NO-system activity, and
diminishing fibrosis and hypertrophy. Moreover, as a relationship
between ANP and estrogens is thus postulated, the effects of the
treatment could be different in male and female SHR.
In order to demonstrate this hypothesis, we investigated the
effects of chronic treatment with ANP on systolic blood pressure,
cardiac NO system, oxidative stress, hypertrophy, fibrosis and
apoptosis in SHR. Moreover, this study also looked into possible
sex-related differences in the response to the treatment.
Materials and Methods
Animals
Ten-week old male and female SHR were purchased from the
Instituto de Investigaciones Me´dicas A. Lanari, Facultad de
Medicina (Universidad de Buenos Aires, Argentina). Rats were
housed in a humidity and temperature-controlled environment
with an automatic 12-hour light-dark cycle. They were fed
standard rat chow from Nutrimentos Purina (Buenos Aires,
Argentina) and provided tap water ad libitum up to the day of
the experiments.
Experimental design
All experimental protocols were performed in accordance with
the Guide for the Care and Use of Laboratory Animals (National
Institutes of Health, Publication No. 85-23, Revised 1996) and
Regulation No. 6344/96 of Argentina’s National Drug, Food and
Medical Technology Administration (ANMAT). Experimental
procedures were approved by the Ethics Committee of the School
of Biochemistry and Pharmacy, Universidad de Buenos Aires.
Protocol
Animals were separated by sex and then randomly assigned to
the ANP-treated group (n = 10): chronic infusion with ANP
(100 ng/h/rat), or the Control group (n = 10): chronic infusion
with NaCl 0.9%, for 14 days. Chronic infusion in both groups was
performed using an Alzet micro-osmotic pump (model 1002),
prepared according to the manufacturer’s instructions, and
implanted subcutaneously between the scapulae under light ether
anesthesia using aseptic technique.
Systolic blood pressure (SBP) was recorded and urine samples
were collected at the end of the experimental period in all groups
of animals. SBP was measured in awake animals (tail cuff method)
with a MP100 Pulse Transducer, PanLab (Quad Bridge Amp,
ADInstruments), and recorded with a polygraph (Quad Bridge
Amp, ADInstruments). Data were obtained using data acquisition
software (PowerLab 8/30 and Labchart, Australia).
The concentration of nitrites and nitrates (NOx), end products
derived from NO metabolism, was determined in urine samples
collected over 24 hours according to the procedure described by
Verdon et al. [23].
Subsequently, animals were sacrificed by decapitation and
hearts were removed and weighed in order to evaluate NOS
activity and expression, oxidative stress, fibrosis and apoptosis.
Determination of NOS activity
NOS activity in the left ventricle (LV) was measured using [14C]
L-arginine as substrate, as described previously [24,25]. 2–3 mm
thick tissue slices were incubated 30 minutes at 37uC in Krebs
solution with 0.5 mCi/ml [14C] L-arginine. The reaction was
stopped by adding 500 ml stop buffer containing 0.5 mM EGTA,
0.5 mM EDTA and 20 mM HEPES (pH 5.5). Tissue samples
were then homogenized in the stop solution and the homogenates
were centrifuged at 12,000 g for 20 minutes.
The supernatants were then applied to a 1 ml Dowex AG 50W-
X8 column (Na+ form, Bio-Rad), hydrated with the stop buffer,
and eluted with 2 ml distilled water. The amount of [14C] L-
citrulline was determined with a liquid scintillation counter
(Wallac 1414 WinSpectral). Specific NOS activity was assessed
in the presence of 1024 M L-Nitro arginine methyl ester (L-
NAME, Sigma). NO production in each tube was normalized to
the weight of the tissue slices incubated with the substrate for equal
periods of time and expressed as picomoles of [14C] L-citrulline
per gram wet weight per minute.
Western blot analysis
Samples of LV tissue containing equal amounts of protein
(0.10 mg protein/lane) were separated by electrophoresis in 7.5%
SDS-polyacrylamide gels, transferred to a nitrocellulose mem-
brane (Amersham G.E. Healthcare), and then incubated with
rabbit polyclonal anti-NOS antibodies (1/500 dilution) and a
horseradish peroxidase-conjugated goat anti-rabbit secondary
antibody (1/5,000 dilution: anti-eNOS, epitope at the NH2
terminus) (Santa Cruz Biotechnology, Santa Cruz, CA). A marker
of b-actin was used as a loading control and data were normalized
to b-actin expression. Samples were revealed by chemilumines-
cence using an enhanced chemiluminescence reagent (Amersham
Pharmacia Biotechnology, Uppsala, Sweden) for 2–4 minutes.
Quantification of the bands was performed by digital image
analysis using a Hewlett-Packard scanner and Totallab analyzer
software (Biodynamics, Seattle, WA). All experiments were
performed in triplicate.
Oxidative stress evaluation
LV slices were homogenized (OMNI MIXER homogenizer) in
30 mM phosphate buffer potassium, pH 7.4, 120 mM KCl (1 g
tissue/10 ml buffer), and centrifuged at 2,500 rpm for 10 minutes
at 4uC. Lipid oxidative damage was assessed by measuring the
extent of formation of 2-thiobarbituric acid reactive substances
Cardia Effects of ANP in SHR: Sex Differences
PLOS ONE | www.plosone.org 2 August 2013 | Volume 8 | Issue 8 | e71992
(TBARS; nmol/mg protein) [26]. Super oxide dismutase (SOD)
activity was assessed by measuring the ability of the homogenate to
inhibit autoxidation of epinephrine, and was expressed as units of
SOD per milligram of protein [27]. Catalase (CAT) activity was
determined by the conversion of hydrogen peroxide to oxygen and
water, and was expressed as picomole per milligram of protein
[28]. The assay described by Flohe´ and Gunzler was used to
measure glutathione peroxidase (GPX) activity, and was expressed
as nanomoles per minute per milligram of protein [29].
In order to measure glutathione content, LV slices were
homogenized in 100 mM phosphate buffer sodium, pH 7.0,
5 mM EDTA (1.6 g tissue/10 ml buffer), and centrifuged at
13,000 rpm for 20 minutes at 4uC. Glutathione concentration was
measured according to the method described by Tietze F. and was
expressed as milligram per milligram of protein [30]. Protein
concentration was determined by the method of Bradford et al.
[31].
Histological evaluation and immunolabeling
LV was cut longitudinally, fixed in phosphate-buffered 10%
formaldehyde, pH 7.2, and embedded in paraffin wax. Tissue
sections (3 mm) were stained with hematoxylin and eosin. Ventricle
morphometric parameters were determined in 10 areas, measur-
ing major and minor diameters and then calculating mean
diameter.
Ventricle sections were stained with the collagen-specific stain
Picrosirius Red to determine the presence of fibrosis, as described
previously [32]. Collagen staining was evaluated and scored: 0 =
normal and slight staining surrounding vascular structures; 1 =
(mild) weak staining that doubles normal label surrounding
vascular structures; 2 = (moderate) moderate staining in the
interstitium surrounding cardiomyocytes; 3 = (severe) strong
staining in the interstitium surrounding cardiomyocytes and
compromising ,25% of the area; and 4 = (very severe) strong
staining in the interstitium surrounding cardiomyocytes and
compromising .25% of the area. A score was assigned to each
section, mainly reflecting the changes in extent rather than in
intensity of staining.
Immunohistochemistry for transforming growth factor beta
(TGF-b) was performed on formalin-fixed, paraffin-embedded
samples sectioned at 5 mm. Serial sections were deparaffinized in
xylene and rehydrated through a graded series of ethyl alcohol and
PBS. Endogenous peroxide was blocked by incubation in
peroxidase blocking reagent DAB (Dako EnVision H + system-
HRP) for 5 minutes. After washing with PBS, sections were
incubated for 40 minutes with primary polyclonal antibody against
Smad protein (H465 sc 7153, dilution 1:100) (Santa Cruz
Biotechnology, Santa Cruz, CA). After washing, sections were
incubated with the secondary antibody. Sections were developed
with 3,39-diaminobenzidine solution as chromogen for 15 minutes,
counterstains with hematoxylin, dehydrated, cleared and mount-
ed. Negative controls were performed by omitting the primary
antibodies. Results are expressed as the percentage of the total
area that presents staining (% stained area/total area).
Tunel
The DeadEnd Colorimetric TUNEL System, a non-radioactive
kit designed to end-label the fragmented DNA of apoptotic cells,
was used as previously described [30]. The number of TUNEL-
positive cells per cardiac area was counted in 20 visual fields
(magnification X400) for each rat.
Histological, immunohistological and TUNEL assays were
analyzed using an Olympus BX51 light microscope equipped
with a digital camera (Qcolor 3, Olympus America, Inc.,
Richmond Hill, Ontario, Canada) and connected to the Image-
Pro Plus 4.5.1.29 software (Media Cybernetics, LP, Silver Spring,
MD, USA). The measurements were performed blindly and under
similar light, gain, offset, and magnification conditions.
Statistical Analysis
All values are expressed as means 6SEM. The Prism program
(Graph Pad Software, Inc., San Diego, CA, USA) was used for
statistical analysis. The mean and standard error of median values
of each variable were calculated for each group. The results of
each variable for each experimental group were analyzed with a
two-way analysis of variance (ANOVA), where one factor was the
different treatments and the other was sex (male or female). The
effects of one factor were tested independently of the effects of the
other, as well as the interaction between both factors. No
interaction between treatments and genotype was found. Multiple
comparisons were performed using a Bonferroni post hoc test. p
value ,0.01 was considered a significant difference.
Results
Effects of chronic treatment with ANP on SBP and the
NO-system
Figure 1A shows SBP in control and ANP-treated male and
female SHR. Male SHR showed higher levels of SBP than
females. Chronic treatment with ANP lowered SBP in both sexes
(Figure 1A).
NO systemic production was evaluated by measurement of
NOx excretion, and basal NOx excretion was found to be higher
in female than in male SHR. ANP chronic infusion increased
NOx excretion in both sexes (Figure 1B).
To verify whether this increase in NOx was associated with an
increase in cardiac NOS activity and/or expression, and whether
any sex differences existed, NOS activity and eNOS expression
were measured in cardiac ventricle. The activity of the enzyme
was higher in female than in male SHR, NOS activity increased
significantly in both sexes after ANP treatment but the response of
cardiac NOS to ANP treatment was more marked in female SHR
(Figure 1C). eNOS protein content was higher in female than in
male ventricles, and ANP increased eNOS expression in both
sexes (Figure 1D).
Study of heart oxidative stress in response to chronic
ANP treatment
In the control group female rats displayed higher levels of
glutathione and lower levels of TBARS when compared to males.
Chronic treatment with ANP increased the levels of glutathione
and reduced TBARS in both sexes. The anti-oxidant enzymes that
participate in the regulation of ROS were then studied and female
rats showed higher basal activity of CAT and SOD, but reduced
GPx activity, compared to males. In addition, chronic treatment
with ANP increased CAT and SOD activity only in male SHR,
while ANP treatment decreased GPx activity in both sexes
(Table 1).
Changes in body and heart dimensions after treatment
with ANP
Body, heart and LV weight were higher in male than in female
rats. In this regard, a significant decrease in these parameters was
noted in male rats after chronic treatment with ANP, but only
heart weight was reduced in treated female rats. The LV/BW
Cardia Effects of ANP in SHR: Sex Differences
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ratio, as a parameter of LV hypertrophy, was higher in male rats,
and it was reduced after ANP treatment (Table 2).
Mean myocyte diameter was measured in LV slices and female
rats showed reduced myocyte size compared with males. ANP
treatment reduced mean cardiomyocyte diameter in both sexes
(Table 2).
Sirius Red staining, TGF-b immunohistochemistry and
apoptosis in cardiac ventricle
LV sections stained with collagen-specific Picrosirius Red
showed that female rats had less fibrosis than male rats and
ANP treatment reduced the staining for collagen type 1 and 3 in
both sexes (Table 3, Figure 2). Immunohistochemistry for TGF-b
as a factor responsible for LV fibrosis in hypertension was also
evaluated, and the same behavior was found: female rats showed a
Figure 1. ANP treatment effects on SBP, NOx, cardiac NOS activity and eNOS expression. (A) SBP: systolic blood pressure; (B) NOx: Nitrites
and nitrates excretion; (C) NOS (nitric oxide synthase) activity; (D) Representative blot of eNOS and b-actin and quantification of the bands of eNOS.
Data are mean 6 SEM (n = 10). *p,0.01 vs. Control male, # p,0.01 vs Control female.
doi:10.1371/journal.pone.0071992.g001
Table 1. Effects of chronic treatment with ANP on oxidative stress in left ventricle of male and female SHR.
Male Female
Control ANP Control ANP
GSH (mg/mg tissue) 0.18360.032 0.26860.047* 0.36560.061* 0.42460.054#
TBARS (nmol/mg prot) 0.31860.036 0.21860.023* 0.15060.019* 0.11460.017#
CAT (pmol/mg prot) 0.18460.042 0.45260.079* 0.55960.084* 0.51360.071
SOD (USOD/mg prot) 11.8961.01 15.2261.09* 15.4561.27* 16.1061.51
GPx (mmol/min.mg prot) 332.1626.4 243.2619.2* 239.4618.1* 198.3611.7#
GSH: glutathione; TBARS: thiobarbituric acid reactive substances; CAT: Catalase; SOD: superoxide dismutase; GPx: gluthatione peroxidase.
Data are mean 6SEM (n = 10).
*p,0.01 vs. Control male;
#p,0.01 vs. Control female.
doi:10.1371/journal.pone.0071992.t001
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lower percentage of staining for this factor than male rats. ANP
treatment reduced staining for TGF-b in both sexes (Table 3,
Figure 3).
Examination of TUNEL-stained LV sections of control rats
revealed no differences between males and females in the number
of apoptotic cells, but treatment with ANP decreased the number
of apoptotic cells in both male and female SHR (Table 3).
Discussion
This is the first experimental in vivo study that shows that
chronic treatment with ANP reduces cardiac oxidative stress,
fibrosis, apoptosis and hypertrophy in a model of hypertension,
increasing NO-system activity. A sex-related difference in the
cardiac response to ANP in SHR is also described.
In previous studies we demonstrated that male SHR showed
increased urinary excretion of NO metabolites and augmented
activity of cardiovascular and renal NOS compared to normo-
tensive animals, indicating that the NO pathway is up-regulated in
this model of hypertension [15,33]. In the present study, we
showed that female SHR exhibit lower SBP than male SHR.
Female SHR also presented an increase in NOx, higher activity
and expression of cardiac eNOS and a reduction in LV oxidative
stress compared to male rats, indicating a sex difference in these
parameters. Our results are consistent with different clinical and
experimental studies that demonstrate sex differences in the
prevalence of hypertension before the onset of menopause. This
Table 2. Body weight and heart dimensions in control and
ANP-treated male and female SHR.
Male Female
Control ANP Control ANP
BW (g) 309.666.31 273.568.72* 206.864.21* 208.763.15
HW/BW (mg/g) 0.48260.020 0.43660.018* 0.46360.021* 0.42160.017#
LV (g) 1.18660.015 0.89460.099* 0.70160.023* 0.66560.013
LV/BW (mg/g) 0.3860.01 0.3360.01* 0.3460.01* 0.3160.01
mCD (mm) 27.8160.34 25.0160.46* 24.0960.69* 20.7160.89#
BW: body weight; HW: heart weight; LV: left ventricle; mCD: mean
cardiomyocyte diameter.
Data are mean 6SEM (n = 10).
*p,0.01 vs. Control male;
#p,0.01 vs. Control female.
doi:10.1371/journal.pone.0071992.t002
Figure 2. Sirius Red staining in left ventricle after treatment with ANP. The red colour of Sirius red staining under the common microscope
indicates total collagen deposits, representative images are from hearts of each group. (A): Control male; (B): ANP male; (C): Control female; (D): ANP
female. All images are in the same magnification 400X. Scale bar = 30 mm.
doi:10.1371/journal.pone.0071992.g002
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fact could be attributed to the beneficial effects of estradiol on the
cardiovascular system, which include vasodilatation by a direct
mechanism and, indirectly, by increasing eNOS activity in blood
vessels [6,34–37]. Furthermore, it has been shown in humans and
animals that NO level is higher in females than in males because
estrogens not only stimulate NO production but also decrease
inactivation of NO by oxygen radicals [8,9,38]. Moreover,
epidemiological and experimental evidence suggests that oxidative
stress is enhanced in males compared with females [39–41]. Our
results show that hearts of female SHR exhibit higher levels of
glutathione and lower content of TBARS than male ones,
indicating a sex difference in cardiac oxidative stress. In addition,
cardiac activity of CAT and SOD was higher in female than in
male SHR, suggesting a more effective antioxidant system in heart
Figure 3. Immunohistochemistry staining for TGF-b in left ventricle after treatment with ANP. Representative micrographs of
immunostained TGF-b in the hearts from each group. (A): Control male; (B): ANP male; (C): Control female; (D): ANP female. All images are in the
same magnification 400X. Scale bar = 30 mm.
doi:10.1371/journal.pone.0071992.g003
Table 3. Effects of chronic treatment with ANP on cardiac fibrosis and apoptosis in male and female SHR.
Male Female
Control ANP Control ANP
SR (Score) 2.3060.09 2.0360.10* 2.0260.12* 1.7560.10#
TGF-b (%) 18.1161.26 11.5161.16* 14.9161.47* 11.4160.96#
Apoptotic/total cells (%) 11.6160.94 5.9760.38* 9.0761.32 5.1660.47#
SR: Sirius red; TGF-b: transforming growth factor beta.
Data are mean 6SEM (n = 10).
*p,0.01 vs. Control male;
#p,0.01 vs. Control female.
doi:10.1371/journal.pone.0071992.t003
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of female SHR. Moreover, higher GPx expression in the heart of
male rats compared with females [42] has been reported. In this
regard, we found increased GPx activity in male SHR compared
with female SHR, probably due to a compensatory response to the
lower levels of glutathione observed in male SHR.
Several studies have shown increased oxidative stress associated
with higher levels of hypertrophy in hearts from male SHR in
comparison to Wistar rats [43]. This study showed that female
SHR presented less LV fibrosis and a lower index of LV
hypertrophy than male SHR. Moreover, mean diameter of
cardiac myocytes was smaller in female than in male rats. We
found that, in this model of hypertension, female rats showed not
only less cardiac fibrosis but also less profibrotic factor TGF-b than
male rats. These results are supported by in vitro findings which
demonstrate that estrogen inhibits the hypertrophic response and
exhibits an antifibrotic effect on the heart by inhibiting transition
from fibroblast to myofibroblast, diminishing the synthesis of
collagen type 1 and 3 and suppressing the profibrotic agent TGF-b
[44].
It has been reported that SHR show higher levels of apoptosis
than WKY [45]. Pelzer T. et al. demonstrated that estradiol
inhibits apoptosis induced by oxidative stress in cardiac myocytes
[46]. In this regard, our results showed that while females exhibit
lower oxidative stress in LV than males, we found no sex
differences in cardiac apoptosis in SHR. On the other hand, it is
well known that ANP is a diuretic, natriuretic and hypotensive
factor. In previous studies, we found that acute treatment with
ANP in normotensive and hypertensive male animals reduces
blood pressure, increasing cardiovascular NOS activity by
interacting with natriuretic peptide receptors NPR-A and NPR-
C [33]. Therefore, we tested the hypothesis that long-term
treatment with ANP induces cardiovascular benefits in SHR and
sex differences are present in this model of hypertension.
Consistent with our hypothesis, we found that this treatment
lowered SBP in both sexes, and it was accompanied by an increase
in NO-system activity and a decrease in oxidative stress in the
heart. The response of cardiac NOS to ANP in female rats was
higher than in males, showing a probable role of estrogen in
enhancement of ANP effects on the NO-system.
Natriuretic peptides were found to attenuate ROS production
by interacting with all three receptor classes. Thus, in hepatocytes
and Kupffer cells, ANP reduces oxidative stress by activation of
NPR-A/B [47]. In turn, enhanced oxidative stress in vascular
smooth muscle cells of SHR was reduced by activation of NPR-C
with its specific agonist, cANP (4–23) [48]. It has been recently
shown that the infusion of human synthetic ANP (carperitide) in
patients with heart failure not only afforded beneficial effects on
hemodynamic performance but also acted as an antioxidant
[49,50]. In addition, in neonatal rat cardiomyocytes cultured with
angiotensin II, several hypertrophic responses such as increase in
cardiomyocyte size and superoxide generation were reduced in the
presence of ANP [20]. Our study supports these findings and
shows that chronic treatment with ANP reduces cardiac oxidative
stress in both male and female SHR, probably due to a decrease in
superoxide production and an increase in NO synthesis. In
addition, the treatment with ANP also increased CAT and SOD
activity in male hearts, contributing to reduce oxidative stress,
which was more marked in male than in female rats.
With respect to the antihypertrophic properties of ANP, Oliver
et al. reported that NPR-A deficiency in mice leads to cardiac
hypertrophy, much higher fibrosis and elevated blood pressure
[51]. In the present study, when SHR were treated with a chronic
infusion of ANP, the index of LV hypertrophy was reduced only in
male rats, which also exhibited a reduction in mean diameter of
myocytes. ANP presents an antifibrotic effect in sexes, reducing
the percentage of collagen type 1 and 3 and diminishing TGF-b in
LV.
In vitro data about the role of ANP in regulation of apoptotic
mechanisms appears controversial. Studies performed by Wu C. et
al. in neonatal rat cardiac myocytes showed that ANP induces
apoptosis, inhibiting de expression of Mcl-1, which is an anti-
apoptotic homolog of Bcls [52]. In contrast, Kato et al. observed
that ANP promotes cardiomyocyte survival by nuclear accumu-
lation of Akt and zyxin (in a cGMP-dependent mechanism) [53].
The present protocol represents the first in vivo study that analyzes
the effects of ANP treatment on apoptosis in the heart, showing
that chronic treatment with the peptide reduces apoptosis in the
cardiac ventricle of both male and female SHR.
It is well known that NO exerts antioxidant, antifibrotic and
antihypertrophic effects in the heart [54,55]. Additionally, in the
present study we demonstrated that ANP increases cardiac eNOS
activity and expression. Based on these findings, we can postulate
that indirect effects of ANP in LV would be mediated, at least in
part, by the increase in NO, which also contributes to reduce
oxidative stress.
Whether sex plays an essential role in the onset of hypertension
complications and organ damage continues to be an issue of
intense debate, but we found that, in this model of hypertension,
female SHR showed less cardiac fibrosis, apoptosis and oxidative
stress in the heart than male SHR. While we must take into
account that males have higher blood pressure values than
females, it is important to consider that blood pressure values in
females are also consistent with target organ damage. On the other
hand, chronic treatment with ANP not only lowered SBP but also
induced antifibrotic, antihypertrophic and antiapoptotic effects on
the heart of male and female SHR, showing more benefits in males
which present major organ damage. In accordance with our
results, the beneficial effects of ANP in hypertension probably
involve activation of the NO-system and reduction in ROS levels.
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